SCHEMBL3004358

SCHEMBL3004358

COc1ccc(OC)c(-c2csc(N3CCC(S(=O)(=O)c4cccc([N+](=O)[O-])c4)CC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REV1 Q9UBZ9 1/20 0.48
MAPT P10636 6/20 0.42
HSD17B10 Q99714 3/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
ALDH1A1 P00352 6/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
RAB9A P51151 2/20 0.41
KMO O15229 1/20 0.41
LMNA P02545 3/20 0.41
HPGD P15428 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR6 P50406 1/20 0.40
TP53 P04637 2/20 0.39
MAPK1 P28482 2/20 0.39
TSHR P16473 1/20 0.39
NPC1 O15118 2/20 0.38
AR P10275 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998804 0.94 AR (0.44) REV1MAPTHSD17B10USP2RECQL
SCHEMBL3013016 0.92 REV1 (0.49) REV1MAPTHSD17B10USP2RECQL
SCHEMBL3018960 0.91 SMN1; SMN2 (0.44) MAPTHSD17B10USP2RECQLMEN1
SCHEMBL3006727 0.88 MAPT (0.53) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3003633 0.88 MAPT (0.56) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3015178 0.87 REV1 (0.52) REV1MAPTHSD17B10USP2RECQL
SCHEMBL3006738 0.87 REV1 (0.54) REV1MAPTHSD17B10USP2RECQL
SCHEMBL3005216 0.87 KMO (0.52) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3023199 0.87 MAPT (0.56) REV1MAPTHSD17B10USP2RECQL
SCHEMBL3012386 0.87 REV1 (0.51) REV1MAPTHSD17B10USP2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA REV1 4692/4885MAPT 18/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.